Canadian Diabetes Association position paper: Antipsychotic medications and associated risks of weight gain and diabetes

Canadian Journal of Diabetes

Volumn 29, Issue 2, 2005, Pages 111-112

  Woo, Vincent ^a   Harris, Stewart B ^b   Houlden, Robyn L ^c  

^a UNIVERSITY OF MANITOBA   (Canada)

^b WESTERN UNIVERSITY   (Canada)

^c QUEEN S UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; CLOZAPINE; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE; ZIPRASIDONE;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; AKATHISIA; ALZHEIMER DISEASE; ARTICLE; BIPOLAR DISORDER; CANADA; CARDIOVASCULAR DISEASE; CAUSE OF DEATH; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE EXACERBATION; DRUG EFFICACY; DRUG INDUCED DISEASE; DYSLIPIDEMIA; DYSTONIA; EXTRAPYRAMIDAL SYNDROME; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; HUMAN; HYPERGLYCEMIA; MAJOR DEPRESSION; MEDICAL SOCIETY; METABOLIC DISORDER; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PARKINSONISM; PREVALENCE; RISK FACTOR; SCHIZOPHRENIA; SIDE EFFECT; TARDIVE DYSKINESIA; UNSPECIFIED SIDE EFFECT; WEIGHT GAIN;

EID: 31544459560     PISSN: 14992671     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (9)

1. American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, North American Association for the Study of Obesity. Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care. 2004;27:596-601.
2. Brown S. Excess mortality of schizophrenia: A meta-analysis. Br J Psychiatry. 2001;171:502-508.
3. Mortensen PB, Juel K. Mortality and causes of death in first admitted schizophrenic patients. Br J Psychiatry. 1993;163:183-189.
4. Canadian Diabetes Association Clinical Practice Guidelines Expert Committee. Canadian Diabetes Association 2003 clinical practice guidelines for the prevention and management of diabetes in Canada. Can J Diabetes. 2003;27(suppl 2):S1-S1S2.
5. Lean ME, Pajonk FG. Patients on atypical antipsychotic drugs: another high-risk group for type 2 diabetes. Diabetes Care. 2003;26:1597-1605.
6. Allison DB, Mentore JL, Moonseong H, et al. Antipsychotic-induced weight gain: A comprehensive research synthesis. Am J Psychiatry. 1999;156:1686-1696.
7. Wilson DR, D'Souza L, Sarkar N, et al. New-onset diabetes and ketoacidosis with atypical antipsychotics. Schizophr Res. 2002;59:1-6.
8. Sussman N. The implications of weight changes with antipsychotic treatment. J Clin Psychopharmacol. 2003;23(3 suppl 1):S21-S26.
9. Sowell MO, Mukhopadhyay N, Cavazzoni P, et al. Hyperglycemic clamp assessment of insulin secretory responses in normal subjects treated with olanzapine, risperidone, or placebo. J Clin Endocrinol Metab. 2002;87:2918-2923.